Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.

Fabrícia DietrichHugo BarcenillaBeatriz TaviraJeanette WahlbergPeter AchenbachJohnny LudvigssonRosaura Casas

Published in: Diabetes/metabolism research and reviews (2021)

GAD-specific immune responses 15 months after lymph node injections of GAD-alum differed from the ones induced by SC administration of the same autoantigen.

Keyphrases

immune response
lymph node
type diabetes
dendritic cells
toll like receptor
neoadjuvant chemotherapy
glycemic control
cardiovascular disease
squamous cell carcinoma
skeletal muscle
insulin resistance
adipose tissue